Skip to main content
SpringerLink
Log in

Screening and Vaccinations in Patients Requiring Systemic Immunosuppression: An Update for Dermatologists

  • Review Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Immunomodulatory agents are becoming an increasingly important tool in the dermatologist’s armamentarium against autoimmune and auto-inflammatory conditions. This review addresses the guidelines for vaccination and screening studies prior to the initiation of immunomodulatory agents. Included are discussions of vaccination schedules, hepatitis vaccination and screening, tuberculosis screening, and specific screening recommendations for antimalarials, azathioprine, cyclosporine, methotrexate, mycophenolate mofetil, tumor necrosis factor-α inhibitors, and newer medications like apremilast and tofacitinib.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Kazlow Stern D, Tripp JM, Ho VC, Lebwohl M. The use of systemic immune moderators in dermatology: an update. Dermatol Clin. 2005;23:259–300.

    PubMed  Google Scholar 

  2. Choy EHS, Isenberg DA. Treatment of dermatomyositis and polymyositis. Rheumatology. 2002;41:7–13.

    CAS  PubMed  Google Scholar 

  3. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61:451–85.

    CAS  PubMed  Google Scholar 

  4. Chang AY, Werth VP. Treatment of cutaneous lupus. Curr Rheumatol Rep. 2011;13:300–7.

    PubMed Central  CAS  PubMed  Google Scholar 

  5. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–50.

    PubMed  Google Scholar 

  6. Blok JL, van Hattem S, Jonkman MF, Horváth B. Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. Br J Dermatol. 2013;168:243–52.

    CAS  PubMed  Google Scholar 

  7. Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007;56:1754–64.

    CAS  PubMed  Google Scholar 

  8. Dixon WG, Kezouh A, Bernatsky S, Suissa S. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis. 2011;70:956–60.

    PubMed Central  CAS  PubMed  Google Scholar 

  9. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 2007;56:1125–33.

    CAS  PubMed  Google Scholar 

  10. Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis. 2011;70:1914–20.

    PubMed Central  CAS  PubMed  Google Scholar 

  11. Stelton CR, Connors DB, Walia SS, Walia HS. Hydrochloroquine retinopathy: characteristic presentation with review of screening. Clin Rheumatol. 2013;32:895–8.

    PubMed  Google Scholar 

  12. Levy GD, Munz SJ, Paschal J, Cohen HB, Pince KJ, Peterson T. Incidence of hydroxychloroquine retinopathy in 1207 patients in a large multicenter outpatient practice. Arthritis Rheum. 1997;40:1482–6.

    CAS  PubMed  Google Scholar 

  13. Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology. 2003;110:1321–6.

    PubMed  Google Scholar 

  14. Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years’ experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol. 2000;14:382–8.

    CAS  PubMed  Google Scholar 

  15. Carneiro SC, Cássia FF, Lamy F, Chagas VLA, Ramos-e-Silva M. Methotrexate and liver function: a study of 13 psoriasis cases treated with different cumulative dosages. J Eur Acad Dermatol Venereol. 2008;22:25–9.

    CAS  PubMed  Google Scholar 

  16. Lindsay K, Fraser AD, Layton A, Goodfield M, Gruss H, Gough A. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology (Oxford). 2009;48:569–72.

    CAS  Google Scholar 

  17. Lu Y, Bousvaros A. Immunizations in children with inflammatory bowel disease treated with immunosuppressive therapy. Gastroenterol Hepatol (N. Y). 2014;10:355–63.

    Google Scholar 

  18. Centers for Disease Control and Prevention. Principles of vaccination. In: Atkinson W, Wolfe S, Hamborsky J, editors. Epidemiol. Prev. Vaccine-Preventable Dis. 12th ed. Washington D.C.: Public Health Foundation; 2012. p. 1–9.

  19. Hilleman MR. Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine. 2000;18:1436–47.

    CAS  PubMed  Google Scholar 

  20. Impact of vaccines universally recommended for children–United States, 1990–1998. MMWR Morb Mortal Wkly Rep. 1999;48:243–8.

  21. Ten great public health achievements–United States, 1900–1999. MMWR Morb Mortal Wkly Rep. 1999;48:241–3.

  22. Wolfson LJ, Strebel PM, Gacic-Dobo M, Hoekstra EJ, McFarland JW, Hersh BS. Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. Lancet. 2007;369:191–200.

    PubMed  Google Scholar 

  23. Sun Z, Chen T, Thorgeirsson SS, Zhan Q, Chen J, Park J-H, et al. Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. Carcinogenesis. 2013;34:1800–5.

    PubMed Central  CAS  PubMed  Google Scholar 

  24. Van Kriekinge G, Castellsagué X, Cibula D, Demarteau N. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths. Vaccine. 2014;32:733–9.

    PubMed  Google Scholar 

  25. Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum. 2004;33:283–8.

    CAS  PubMed  Google Scholar 

  26. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;1:CD000422.

    PubMed  Google Scholar 

  27. Advisory Committee on Immunization Practices. Grading of recommendations, assessment, development, and evaluation (GRADE) for pneumococcal vaccines for immunocompromised adults. Morb Mortal Wkly Rep. 2012;61:816–9.

    Google Scholar 

  28. Advisory Committee on Immunization Practices. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the advisory committee on immunization practices (ACIP). Morb Mortal Wkly Rep. 2012;61:816–9.

    Google Scholar 

  29. Melmed GY, Agarwal N, Frenck RW, Ippoliti AF, Ibanez P, Papadakis KA, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:148–54.

    PubMed  Google Scholar 

  30. Mease PJ, Ritchlin CT, Martin RW, Gottlieb AB, Baumgartner SW, Burge DJ, et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol. 2004;31:1356–61.

    CAS  PubMed  Google Scholar 

  31. Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol. 2007;34:272–9.

    CAS  PubMed  Google Scholar 

  32. Kapetanovic MC, Roseman C, Jönsson G, Truedsson L, Saxne T, Geborek P. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum. 2011;63:3723–32.

    CAS  PubMed  Google Scholar 

  33. Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jönsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006;45:106–11.

    CAS  Google Scholar 

  34. Li Y, Li Z, Lin H, Chen X, Li B. Primary cutaneous blastic plasmacytoid dendritic cell neoplasm without extracutaneous manifestation: case report and review of the literature. Pathol Res Pract. 2011;207:55–9 (Elsevier GmbH.).

    PubMed  Google Scholar 

  35. Wasan SK, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol. 2010;105:1231–8.

    PubMed  Google Scholar 

  36. National, state, and urban area vaccination coverage among children aged 19–35 months–United States, 2005. MMWR Morb Mortal Wkly Rep. 2006;55:988–93.

  37. Hepatitis B vaccination coverage among adults–United States, 2004. MMWR Morb Mortal Wkly Rep. 2006;55:509–11.

  38. Kroger AT, Sumaya CV, Pickering LK, Atkinson WL. General recommendations on immunization: recommendations of the advisory committee on immunization. MMWR Morb Mortal Wkly Rep. 2011;60:1–60.

    Google Scholar 

  39. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2008;57:1–30 (quiz CE2–CE4).

    PubMed  Google Scholar 

  40. McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the advisory committee on immunization practices (ACIP). Morb Mortal Wkly Rep. 2013;62:1–34.

    Google Scholar 

  41. Zachariah P, Posner A, Stockwell MS, Dayan PS, Sonnett FM, Graham PL, et al. Vaccination rates for measles, mumps, rubella, and influenza among children presenting to a pediatric emergency department in New York City. J Pediatric Infect Dis Soc. 2014;1–4.

  42. Mazurek GH, Jereb J, Veron A, LoBue P, Goldberg S, Castro K. Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection—United States, 2010. Morb Mortal Wkly Rep. 2010;59:1–25.

    Google Scholar 

  43. Jensen P, Lambert L, Iademarco MF, Ridzon R. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. Morb Mortal Wkly Rep. 2005;54:1–141.

    Google Scholar 

  44. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149:177–84.

    PubMed Central  PubMed  Google Scholar 

  45. Adams LV, Waddell RD, Von Reyn CF. T-SPOT.TB Test(R) results in adults with Mycobacterium avium complex pulmonary disease. Scand J Infect Dis. 2008;40:196–203.

    PubMed  Google Scholar 

  46. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007;146:340–54.

    PubMed  Google Scholar 

  47. Sester M, Sotgiu G, Lange C, Giehl C, Girardi E, Migliori GB, et al. Interferon-γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2011;37:100–11.

    CAS  PubMed  Google Scholar 

  48. Metcalfe JZ, Everett CK, Steingart KR, Cattamanchi A, Huang L, Hopewell PC, et al. Interferon-γ release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. J Infect Dis. 2011;204(Suppl):S1120–9.

    PubMed Central  PubMed  Google Scholar 

  49. Cattamanchi A, Smith R, Steingart KR, Metcalfe JZ, Date A, Coleman C, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2011;56:230–8.

    PubMed Central  CAS  PubMed  Google Scholar 

  50. Ledingham J, Wilkinson C, Deighton C. British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments. Rheumatology (Oxford). 2005;44:1205–6.

    CAS  Google Scholar 

  51. Laurenti R, Giovannangeli F, Gubinelli E, Viviano MT, Errico A, Leoni L, et al. Long-term safety of anti-TNF adalimumab in HBc antibody-positive psoriatic arthritis patients: a retrospective case series of 8 patients. Immunol: Clin Dev; 2013.

    Google Scholar 

  52. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol. 2007;46:160–70.

    PubMed  Google Scholar 

  53. Montiel PM, Solis JA, Chirinos JA, Casis BA, Sánchez F, Rodríguez S. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int. 2008;28:718–20.

    PubMed  Google Scholar 

  54. Mast EE, Weinbaum C, Fiore A, Alter M, Bell B, Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the advisory committee on immunization practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006;55(RR-16):1–33.

    PubMed  Google Scholar 

  55. Smith RA, Manassaram-Baptiste D, Brooks D, Cokkinides V, Doroshenk M, Saslow D, et al. Cancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2014;64:30–51.

    PubMed  Google Scholar 

  56. US Preventive Services Task Force. Screening for HIV: recommendation statement. Ann Intern Med. 2005;143(1):32–7.

    Google Scholar 

  57. Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol. 2012;42:145–53.

    CAS  PubMed  Google Scholar 

  58. Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther. 2007;20:160–74.

    PubMed  Google Scholar 

  59. Marmor MF, Kellner U, Lai TYY, Lyons JS, Mieler WF. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118:415–22.

    PubMed  Google Scholar 

  60. Tang C, Godfrey T, Stawell R, Nikpour M. Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. Intern Med J. 2012;42:968–78.

    CAS  PubMed  Google Scholar 

  61. Pamba A, Richardson ND, Carter N, Duparc S, Premji Z, Tiono AB, et al. Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone. Blood. 2012;120:4123–33.

    CAS  PubMed  Google Scholar 

  62. Plaquenil (Hydroxychloroquine sulfate, USP). http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed 29 Sept 2014.

  63. Meggitt SJ, Anstey AV, Mohd Mustapa MF, Reynolds NJ, Wakelin S. British Association of Dermatologists’ guidelines for the safe and effective prescribing of azathioprine 2011. Br J Dermatol. 2011;165:711–34.

    CAS  PubMed  Google Scholar 

  64. Caufield M, Tom WL. Oral azathioprine for recalcitrant pediatric atopic dermatitis: clinical response and thiopurine monitoring. J Am Acad Dermatol. 2013;68:29–35.

    PubMed Central  CAS  PubMed  Google Scholar 

  65. Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation. 2006;82:1698–702.

    CAS  PubMed  Google Scholar 

  66. Langagergaard V, Pedersen L, Gislum M, Nørgard B, Sørensen HT. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: a Danish nationwide cohort study. Aliment Pharmacol Ther. 2007;25:73–81.

    CAS  PubMed  Google Scholar 

  67. Goldstein LH, Dolinsky G, Greenberg R, Schaefer C, Cohen-Kerem R, Diav-Citrin O, et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol. 2007;79:696–701.

    CAS  PubMed  Google Scholar 

  68. Bajaj JS, Saeian K, Varma RR, Franco J, Knox JF, Podoll J, et al. Increased rates of early adverse reaction to azathioprine in patients with Crohn’s disease compared to autoimmune hepatitis: a tertiary referral center experience. Am J Gastroenterol. 2005;100:1121–5.

    CAS  PubMed  Google Scholar 

  69. Lennard L. Implementation of TPMT testing. Br J Clin Pharmacol. 2014;77:704–14.

    PubMed Central  PubMed  Google Scholar 

  70. Imuran (azathioprine) product information. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed 29 Sept 2014.

  71. TPMT testing before azathioprine therapy? Drug Ther Bull. 2009;47:9–12.

  72. Richard VS, Al-Ismail D, Salamat A. Should we test TPMT enzyme levels before starting azathioprine? Hematology. 2007;12:359–60.

    CAS  PubMed  Google Scholar 

  73. Van den Reek JMPA, van Lümig PPM, Janssen M, Schers HJ, Hendriks JCM, van de Kerkhof PCM, et al. Increased incidence of squamous cell carcinoma of the skin after long-term treatment with azathioprine in patients with auto-immune inflammatory rheumatic diseases. J Eur Acad Dermatol Venereol. 2014;28:27–33.

    PubMed  Google Scholar 

  74. Xiao Z, Shan J, Li C, Luo L, Lu J, Li S, et al. Mechanisms of cyclosporine-induced renal cell apoptosis: a systematic review. Am J Nephrol. 2013;37:30–40.

    CAS  PubMed  Google Scholar 

  75. Hoorn EJ, Walsh SB, McCormick JA, Zietse R, Unwin RJ, Ellison DH. Pathogenesis of calcineurin inhibitor-induced hypertension. J Nephrol. 2012;25:269–75.

    PubMed Central  CAS  PubMed  Google Scholar 

  76. Weir MR. Therapeutic benefits of calcium channel blockers in cyclosporine-treated organ transplant recipients: blood pressure control and immunosuppression. Am J Med. 1991;90:S32–6.

    Google Scholar 

  77. Chan ESL, Cronstein BN. Methotrexate–how does it really work? Nat Rev Rheumatol. 2010;6:175–8.

    CAS  PubMed  Google Scholar 

  78. Griffiths C, Barker J. Pathogenesis and clinical features of psoriasis. Lancet. 2007;270:263–71.

    Google Scholar 

  79. Collin B, Rajaratnam R, Lim R, Lewis H. A retrospective analysis of 34 patients with cutaneous sarcoidosis assessed in a dermatology department. Clin Exp Dermatol. 2010;35:131–4.

    CAS  PubMed  Google Scholar 

  80. Morganroth PA, Kreider ME, Okawa J, Taylor L, Werth VP. Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations. Arch Dermatol. 2010;146:729–38.

    PubMed Central  PubMed  Google Scholar 

  81. Tillie-Leblond I, Wislez M, Valeyre D, Crestani B, Rabbat A, Israel-Biet D, et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax. 2008;63:53–9.

    CAS  PubMed  Google Scholar 

  82. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford). 2004;43:143–7.

    CAS  Google Scholar 

  83. Barker J, Horn EJ, Lebwohl M, Warren RB, Nast A, Rosenberg W, et al. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol. 2011;25:758–64.

    CAS  PubMed  Google Scholar 

  84. Collin B, Srinathan SK, Finch TM. Methotrexate: prescribing and monitoring practices among the consultant membership of the British Association of Dermatologists. Br J Dermatol. 2008;158:793–800.

    CAS  PubMed  Google Scholar 

  85. Gromnica-Ihle E, Krüger K. Use of methotrexate in young patients with respect to the reproductive system. Clin Exp Rheumatol. 2010;28:S80–4.

    CAS  PubMed  Google Scholar 

  86. Weber-Schoendorfer C, Hoeltzenbein M, Wacker E, Meister R, Schaefer C. No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study. Rheumatology (Oxford). 2014;53:757–63.

    CAS  Google Scholar 

  87. Klieger-Grossmann C, Chitayat D, Lavign S, Kao K, Garcia-Bournissen F, Quinn D, et al. Prenatal exposure to mycophenolate mofetil: an updated estimate. J Obstet Gynaecol Can. 2010;32:794–7.

    PubMed  Google Scholar 

  88. Molloy ES. PML and rheumatology: the contribution of disease and drugs. Cleve Clin J Med. 2011;78(Suppl 2):S28–32.

    PubMed  Google Scholar 

  89. Atcheson BA, Taylor PJ, Kirkpatrick CMJ, Duffull SB, Mudge DW, Pillans PI, et al. Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther Drug Monit. 2004;26:284–6.

    CAS  PubMed  Google Scholar 

  90. Le Ray C, Coulomb A, Elefant E, Frydman R, Audibert F. Mycophenolate mofetil in pregnancy after renal transplantation: a case of major fetal malformations. Obstet Gynecol. 2004;103:1091–4.

    PubMed  Google Scholar 

  91. Anderka MT, Lin AE, Abuelo DN, Mitchell AA, Rasmussen SA. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A. 2009;149A:1241–8.

    PubMed  Google Scholar 

  92. CellCept (mycophenolate). http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=CELLCEPT. Accessed 29 Sept 2014.

  93. D’Haens GR, Panaccione R, Higgins PDR, Vermeire S, Gassull M, Chowers Y, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199–212 (quiz 213).

    PubMed  Google Scholar 

  94. Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis. 2011;70(Suppl 1):i2–36.

    PubMed  Google Scholar 

  95. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762–84.

    CAS  PubMed  Google Scholar 

  96. Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital. Int J Rheum Dis. 2009;12:118–24.

    PubMed  Google Scholar 

  97. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098–104.

    CAS  PubMed  Google Scholar 

  98. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum. 2009;60:1884–94.

    PubMed Central  CAS  PubMed  Google Scholar 

  99. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38:1261–5.

    CAS  PubMed  Google Scholar 

  100. Chung S-J, Kim JK, Park M-C, Park Y-B, Lee S-K. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol. 2009;36:2416–20.

    CAS  PubMed  Google Scholar 

  101. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis. 2004;63(Suppl 2):ii18–24.

    PubMed Central  CAS  PubMed  Google Scholar 

  102. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH trial). Circulation. 2003;107:3133–40.

    CAS  PubMed  Google Scholar 

  103. Kwon HJ. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003;138:807.

    PubMed  Google Scholar 

  104. Bernatsky S, Renoux C, Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures. Ann Rheum Dis. 2010;69:1691–3.

    CAS  PubMed  Google Scholar 

  105. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44:2862–9.

    CAS  PubMed  Google Scholar 

  106. Fernández-Espartero MC, Pérez-Zafrilla B, Naranjo A, Esteban C, Ortiz AM, Gómez-Reino JJ, et al. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum. 2011;40:330–7.

    PubMed  Google Scholar 

  107. Magnano MD, Robinson WH, Genovese MC. Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol. 2004;22:S134–40.

    CAS  PubMed  Google Scholar 

  108. Nakou M, Katsikas G, Sidiropoulos P, Bertsias G, Papadimitraki E, Raptopoulou A, et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther. 2009;11:R131.

    PubMed Central  PubMed  Google Scholar 

  109. Bukhari M, Abernethy R, Deighton C, Ding T, Hyrich K, Lunt M, et al. BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2011;50:2311–3.

    Google Scholar 

  110. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43:209–20.

    CAS  PubMed  Google Scholar 

  111. Skrabs C, Müller C, Agis H, Mannhalter C, Jäger U. Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge. Leukemia. 2002;16:1884–6.

    CAS  PubMed  Google Scholar 

  112. Viganò M, Mangia G, Lampertico P. Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy. Expert Opin Biol Ther. 2014;14:1019–31.

    PubMed  Google Scholar 

  113. Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother. 2005;11:189–91.

    PubMed  Google Scholar 

  114. Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:909–20.

    PubMed Central  CAS  PubMed  Google Scholar 

  115. Van Vollenhoven RF, Emery P, Bingham CO, Keystone EC, Fleischmann R, Furst DE, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010;37:558–67.

    PubMed  Google Scholar 

  116. Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012;380:738–46.

    CAS  PubMed  Google Scholar 

  117. Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66(10):2675–84.

    PubMed Central  CAS  PubMed  Google Scholar 

  118. Maiga M, Lun S, Guo H, Winglee K, Ammerman NC, Bishai WR. Risk of tuberculosis reactivation with tofacitinib (CP-690550). J Infect Dis. 2012;205:1705–8.

    PubMed Central  CAS  PubMed  Google Scholar 

  119. McInnes IB, Kim H-Y, Lee S-H, Mandel D, Song Y-W, Connell CA, et al. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Ann Rheum Dis. 2014;73:124–31.

    CAS  PubMed  Google Scholar 

  120. Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2012;64:617–29.

    CAS  PubMed  Google Scholar 

  121. Chiu H-Y, Chen C-H, Wu M-S, Cheng Y-P, Tsai T-F. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol. 2013;169:1295–303.

    CAS  PubMed  Google Scholar 

  122. Tsai T-F, Ho V, Song M, Szapary P, Kato T, Wasfi Y, et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol. 2012;167:1145–52.

    CAS  PubMed  Google Scholar 

  123. Tsai T-F, Chiu H-Y, Song M, Chan D. A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial. Br J Dermatol. 2013;168:444–6.

    PubMed  Google Scholar 

Download references

Disclosures

No funding was received for the preparation of this article.

Amrita Goyal has no conflicts of interest. Kavita Goyal has no conflicts of interest. Dr. Joseph Merola has received research funding from and consulted for Biogen IDEC; is on the advisory boards for AbbVie, Amgen, Eli Lilly, and Novartis; is an investigator for Amgen, Pfizer, and Biogen IDEC; and is a speaker for and has participated in licensed outcome measures for AbbVie.

Author information

Authors and Affiliations

  1. Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Amrita Goyal & Joseph F. Merola

  2. Drexel University College of Medicine, Philadelphia, PA, USA

    Kavita Goyal

Authors
  1. Amrita Goyal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kavita Goyal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph F. Merola
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph F. Merola.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Goyal, A., Goyal, K. & Merola, J.F. Screening and Vaccinations in Patients Requiring Systemic Immunosuppression: An Update for Dermatologists. Am J Clin Dermatol 16, 179–195 (2015). https://doi.org/10.1007/s40257-015-0124-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40257-015-0124-x

Keywords

Search

Navigation